Pembrolizumab Plus Axitinib and the Future of Further-line mRCC Treatments
By Nazli Dizman, MD - Last Updated: May 18, 2023Nazli Dizman, MD, an Internal Medicine Resident at Yale University, discusses the combination of pembrolizumab and axitinib as a second- and further-line treatment of metastatic renal cell carcinoma.
Dr. Dizman describes other second- and further-line treatments that are commonly administered to patients with mRCC, as well as how the design of future trials testing novel immunotherapy combinations for treating mRCC may be influenced by her recent study.
View Dr. Dizman’s comments on the factors that may contribute to positive outcomes for patients receiving pembrolizumab/axitinib.
Related Posts
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Dr. Dizman describes the factors that may contribute to positive outcomes in patients receiving pembrolizumab/axitinib.
The COSMIC-313 trial showed that cabozantinib with nivolumab and ipilimumab resulted in longer progression-free survival.
670 Madison Ave.
Manalapan, NJ 07726